SecurityCCCR / China Commercial Credit, Inc. (16891K103)
Institutional Owners9 (1 N-Q Owners)
Institutional Shares4,383,310 - 21.64% (ex. N-Q)
Common Shares Outstanding20,250,915 shares (as of 2017-12-31)
Institutional Value$ 77,000 USD (ex. N-Q)

Institutional Stock Ownership and Shareholders

CCCR / China Commercial Credit, Inc. Institutional Ownership

China Commercial Credit, Inc. (NASDAQ:CCCR) has 9 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 4,383,310 shares. Largest shareholders include Zhang Shuxiang, Ma Qun, Barclays Plc, Virtu Financial LLC, Susquehanna International Group, Llp, Geode Capital Management, Llc, UBS Group AG, and Morgan Stanley.
China Commercial Credit, Inc. (NASDAQ:CCCR) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/cccr"><img src="https://images.fintel.io/us-cccr-so.png" alt="CCCR / China Commercial Credit, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR TWO SIGMA SECURITIES, LLC 18,816 0 -100.00 26 0 -100.00
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 16,811 0 -100.00 23 0 -100.00
2018-02-13 SC 13D Zhang Shuxiang 2,549,322
2018-05-14 13F-HR Virtu Financial LLC 61,257 16,057 -73.79 85 18 -78.82
2018-04-27 N-Q Fidelity Concord Street Trust (see advisory)
2018-05-15 13F-HR BARCLAYS PLC 18,995 21
2018-05-15 13F-HR UBS Group AG 3,842 8,899 131.62 5 10 100.00
2018-02-14 SC 13D/A Ma Qun 1,764,915 1,764,915 0.00
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 11,141 11,141 0.00 15 12 -20.00
2018-05-14 13F-HR MORGAN STANLEY 500 500 0.00 1 1 0.00
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 13,481 15

Form N-Q Advisory - Experimental Feature Here!

We have recently started to include coverage of N-Q filers in our ownership database. N-Q forms are unstructured and difficult for machines to parse into accurate financial data.

However, Because of the large number of these institutions and this difficulty in tracking their positions, they represent a significant, yet hidden, market force. In an effort to widen our ownership coverage and provide greater transparency, we are testing various ways to expose these owners in an accurate manner. This early version of the crawler simply identifies mentions of companies in the N-Q forms.

Limitations:

  • We only list underlying securities (the ordinary shares), even though the actual security held might be a derivative or a related bond issue. For example, although the institution is shown on this security page ( CCCR / China Commercial Credit, Inc. ), the institution may actually own a related security such as a preferred share or a bond. To find out the exact security, click on the institution link and then follow the link to the actual "N-Q".
  • We only list fund sponsors as institutions, even though the security might be held within a fund operated by the listed institution.. For example, the institution listed in the table as the owner is probably a sponsor of a family of ETFs or mutual funds. If so, then this security is owned by a fund or several funds within the family, and not directly owned by the listed institution. The crawler is not yet able to place these holdings within the individual funds. Atain, you must review the actual filing to see the detail.

These limitations are significant but we believe that the increased transparency outweights the limitations. Future revisions of the crawler will resolve these limitations. Use this information at your own risk!

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

20h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

20h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

BRIEF-China Commercial Credit Announces Launch Of Luxury Car Rental Business

2018-05-02 reuters
* CHINA COMMERCIAL CREDIT INC - CCCR PLANS TO RAISE US$3 MILLION TO FINANCE VEHICLE PURCHASES AND GENERAL OPERATION OF BATCAR Source text for Eikon: Further company coverage: (4-1)

BRIEF-China Commercial Credit Says Received Notice From Sorghum Investment Holdings Stating That Agreement Dated Aug 9, 2017 Is Being Terminated​

2018-01-03 reuters
* CHINA COMMERCIAL CREDIT - ‍ON DEC 29, CO RECEIVED NOTICE FROM SORGHUM INVESTMENT HOLDINGS STATING THAT AGREEMENT DATED AUG 9, 2017 IS BEING TERMINATED​ (4-1)

CUSIP: 16891K103